Reformulation has Ruled in Neurology Dealmaking--Until Now

01 Nov 2006

The big deals in other therapeutic areas focus on novel molecules, in neurology, most focus on formulations of existing molecules. There just hasn't been a lot of novel material that's piqued the interest of licensees, at least in part because of the risk of developing novel neurology compounds. But as Windhover's Therapeutic Alliances: Neuroscience conference showed, much of the new, licensable pipeline is very novel indeed.

In terms of average value, neurology alliances don't compare badly to other therapeutic categories. A bit smaller, overall, than cardiovascular and oncology, but the differences aren't huge. (See Exhibit 1)

But the kinds of products involved in the deals are very different. By and large, the big deals in other...